Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00068081
• Date of registration: 05/09/2003
• Primary sponsor: NeurogesX
• Public title: Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
• Scientific title: A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
• Date of first enrolment: October 2003
• Target sample size: 150
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00068081
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment

Countries of recruitment

United States

Key inclusion & exclusion criteria

Inclusion Criteria:

- At least 18 years of age.

- Be in good health.

- Diagnosis of postherpetic neuralgia (PHN) made by the primary treating physician or
Investigator, and at least 3 months post-vesicle crusting.

- Screening Pain Sum Score of 12 to 36.

- Intact, unbroken skin over the painful area(s) to be treated.

- If taking chronic pain medications, be on a stable (not PRN) regimen for at least 21
days prior to Treatment Visit (Day 0) and willing to maintain medications at same
stable dose(s) and schedule throughout the study.

- Female subjects with child-bearing potential must have a negative serum beta hCG
pregnancy test, to be performed at the Screening Visit.

- All subjects must be willing to use effective methods of birth control and/or refrain
from participating in a conception process during the study and for 30 days following
experimental drug exposure.

- Be willing and able to comply with protocol requirements for the duration of study
participation. (Such requirements include, but are not limited to: completing a
daily pain diary, attending all study visits, and refraining from elective surgery
and extensive travel during study participation.)

Exclusion Criteria:

- Concomitant opioid medication, unless orally or transdermally administered and not
exceeding a total daily dose of morphine 60 mg/day, or equivalent. Parenteral opioid
use is excluded, regardless of dose.

- Unavailability of an effective rescue medication strategy for the subject, such as
unwillingness to use opioid analgesics during treatment, or high tolerance to opioids
precluding the ability to relieve treatment-associated discomfort with Roxicodone®,
as judged by the Investigator.

- Active substance abuse or history of chronic substance abuse within the past year, or
prior chronic substance abuse judged likely to recur during the study period by the
investigator.

- Recent use (within 21 days preceding the Treatment Visit [Day 0]) of any topically
applied pain medication, such as non-steroidal anti-inflammatory drugs, menthol,
methyl salicylate, local anesthetics (including Lidoderm®), steroids or capsaicin
products on the painful areas.

- Current use of any investigational agent, or Class 1 anti-arrhythmic drugs (such as
tocainide and mexiletine).

- Significant pain of an etiology other than PHN, for example, compression-related
neuropathies (e.g., spinal stenosis) or fibromyalgia or arthritis. Subjects must not
have significant ongoing pain from other cause(s) that may interfere with judging
PHN-related pain.

- Painful PHN areas located only on the face, above the hairline of the scalp, and/or
in proximity to mucous membranes. (Investigational treatment with NGX-4010 is not
allowed in these areas.)

- Any implanted medical device (spinal cord stimulator, intrathecal pump or peripheral
nerve stimulator) for the treatment of neuropathic pain.

- Hypersensitivity to capsaicin (i.e., chili peppers or Over-the-Counter (OTC)
capsaicin products), local anesthetics, Roxicodone® or adhesives.

- Significant ongoing or untreated abnormalities in cardiac, renal, hepatic, or
pulmonary function that may interfere either with the ability to complete the study
or the evaluation of adverse events.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Herpes Zoster

Neuralgia

Pain

Peripheral Nervous System Diseases

Intervention(s)

Drug: Capsaicin Dermal Patch

Secondary ID(s)

C110

Source(s) of Monetary Support

Please refer to primary and secondary sponsors